IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Quaity of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Chen, G.1; Feng, J.2; Zhou, C.3; Wu, Y. -L.4; Liu, X. -Q.5; Wang, C.6; Zhang, S.7; Wang, J.8; Zhou, S.3; Ren, S.3; Lu, S.9; Zhang, L.10; Hu, C. -P.11; Hu, C.12; Luo, Y.13; Chen, L.14; Ye, M.15; Huang, J.16; Zhi, X.17; Zhang, Y.18; Xiu, Q.19; Ma, J.20; Zhang, L.21; You, C.22
关键词Chemotherapy Egfr Mutations Erlotinib Non-small-cell Lung Cancer (Nsclc) Quality Of Life (Qol)
刊名ANNALS OF ONCOLOGY
2013-06-01
DOI10.1093/annonc/mdt012
24期:6页:1615-1622
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]FACTOR RECEPTOR MUTATIONS ; MULTICENTER ; GEFITINIB ; EFFICACY
英文摘要

Background: The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). This report describes the quality of life (QoL) and updated PFS analyses from this study.

Patients and methods: Chinese patients >= 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). The primary efficacy end point was PFS; QoL was assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire, Trial Outcome Index (TOI) and Lung Cancer Subscale (LCS).

Results: Patients receiving erlotinib experienced clinically relevant improvements in QoL compared with the chemotherapy group in total FACT-L, TOI and LCS (P < 0.0001 for all scales). Erlotinib scored better than chemotherapy for all FACT-L subscales from baseline to cycles 2 and 4 (non-significant). In the updated analysis, PFS was significantly longer for erlotinib than chemotherapy (median PFS 13.7 versus 4.6 months; HR = 0.164, 95% CI = 0.105-0.256; P < 0.0001), which was similar to the previously reported primary analysis.

Conclusion: Erlotinib improves QoL compared with standard chemotherapy in the first-line treatment of patients with EGFR mutation-positive advanced NSCLC.

语种英语
WOS记录号WOS:000320741500029
项目编号06DZ19502
资助机构Shanghai Pulmonary Hospital ; Chinese Thoracic Oncology Group (C-TONG) ; F. Hoffmann-La Roche (China) ; Science and Technology Commission of Shanghai Municipality
引用统计
被引频次:52[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54593
专题北京大学临床肿瘤学院
北京大学第二临床医学院_血液科
作者单位1.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
2.Jiangsu Prov Canc Hosp, Nanjing, Jiangsu, Peoples R China
3.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Oncol, Shanghai 200433, Peoples R China
4.Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
5.Acad Mil Med Sci, Hosp 307, Ctr Canc, Dept Pulm Oncol, Beijing, Peoples R China
6.Tianjin Canc Hosp, Dept Med Oncol, Tianjin, Peoples R China
7.Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
8.Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
9.Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
10.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
11.Xiangya Hosp, Changsha, Hunan, Peoples R China
12.Cent S Univ, Xangya Hosp 2, Changsha, Hunan, Peoples R China
13.Hunan Prov Canc Hosp, Changsha, Hunan, Peoples R China
14.Shantou Univ, Coll Med, Canc Hosp, Shantou, Peoples R China
15.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai 200030, Peoples R China
16.Suzhou Univ, Affiliated Hosp 1, Suzhou 215006, Peoples R China
17.Capital Med Univ, Xuanwu Hosp, Dept Thorac Surg, Beijing, Peoples R China
18.Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
19.Second Mil Med Univ, Changzhen Hosp, Shanghai, Peoples R China
20.Harbin Inst Hematol & Oncol, Harbin, Peoples R China
21.Peking Union Med Coll, Beijing 100021, Peoples R China
22.Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Chen, G.,Feng, J.,Zhou, C.,et al. Quaity of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)[J]. ANNALS OF ONCOLOGY,2013,24(6):1615-1622.
APA Chen, G..,Feng, J..,Zhou, C..,Wu, Y. -L..,Liu, X. -Q..,...&You, C..(2013).Quaity of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).ANNALS OF ONCOLOGY,24(6),1615-1622.
MLA Chen, G.,et al."Quaity of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)".ANNALS OF ONCOLOGY 24.6(2013):1615-1622.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, G.]的文章
[Feng, J.]的文章
[Zhou, C.]的文章
百度学术
百度学术中相似的文章
[Chen, G.]的文章
[Feng, J.]的文章
[Zhou, C.]的文章
必应学术
必应学术中相似的文章
[Chen, G.]的文章
[Feng, J.]的文章
[Zhou, C.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。